Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hannah E. Carter has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Anubama Rajan

    TAILOR Labs, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, USA

    5 shared publications
  • Anthony W. Maresso

    TAILOR Labs, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, USA

    3 shared publications
  • Anthony William Maresso

    Department of Molecular Virology and Microbiology, Baylor College of Medicine

    2 shared publications
  • Fernando H. Martins

    Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, USA

    2 shared publications
  • Mary K. Estes

    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States

    2 shared publications
  • Matthew J. Robertson

    Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United States

    2 shared publications

Latest Publications

  • Enterococcus faecalis-derived adenine enhances enterohaemorrhagic Escherichia coli Type 3 Secretion System-dependent virulence

    by Fernando H. Martins, Thibaut Rosay, Anubama Rajan, Hannah E. Carter, Tayah Turocy, Andres Mejia, Jason M. Crawford, Anthony W. Maresso, Vanessa Sperandio

    Interactions between microbiota and enteric pathogens can promote colonization resistance or enhance pathogenesis. The pathobiont Enterococcus faecalis increases enterohaemorrhagic E. coli (EHEC) virulence by upregulating Type 3 Secretion System (T3SS) expression, effector translocation, and attaching and effacing (AE) lesion formation on enterocytes, but the mechanisms underlying this remain unknown. Using co-infection of organoids, metabolomics, supplementation experiments and bacterial genetics, here we show that co-culture of EHEC with E. faecalis increases the xanthine-hypoxanthine pathway activity and adenine biosynthesis. Adenine or E. faecalis promoted T3SS gene expression, while transcriptomics showed upregulation of adeP expression, which encodes an adenine importer. Mechanistically, adenine relieved High hemolysin activity (Hha)-dependent repression of T3SS gene expression in EHEC and promoted AE lesion formation in an AdeP-dependent manner. Microbiota-derived purines, such as adenine, support multiple beneficial host responses; however, our data show that this metabolite also increases EHEC virulence, highlighting the complexity of pathogen–microbiota–host interactions in the gut.


  • Open Access

    Role of the Water–Metal Ion Bridge in Quinolone Interactions with Escherichia coli Gyrase

    by Hannah E. Carter, Baylee Wildman, Heidi A. Schwanz, Robert J. Kerns, Katie J. Aldred

    Fluoroquinolones are an important class of antibacterials, and rising levels of resistance threaten their clinical efficacy. Gaining a more full understanding of their mechanism of action against their target enzymes—the bacterial type II topoisomerases gyrase and topoisomerase IV—may allow us to rationally design quinolone-based drugs that overcome resistance. As a step toward this goal, we investigated whether the water–metal ion bridge that has been found to mediate the major point of interaction between Escherichia coli topoisomerase IV and Bacillus anthracis topoisomerase IV and gyrase, as well as Mycobacterium tuberculosis gyrase, exists in E. coli gyrase. This is the first investigation of the water–metal ion bridge and its function in a Gram-negative gyrase. Evidence suggests that the water–metal ion bridge does exist in quinolone interactions with this enzyme and, unlike the Gram-positive B. anthracis gyrase, does use both conserved residues (serine and acidic) as bridge anchors. Furthermore, this interaction appears to play a positioning role. These findings raise the possibility that the water–metal ion bridge is a universal point of interaction between quinolones and type II topoisomerases and that it functions primarily as a binding contact in Gram-positive species and primarily as a positioning interaction in Gram-negative species. Future studies will explore this possibility.


  • Open Access

    Interactions between Enterohemorrhagic Escherichia coli (EHEC) and Gut Commensals at the Interface of Human Colonoids

    by Fernando H. Martins, Anubama Rajan, Hannah E. Carter, Hamid R. Baniasadi, Anthony W. Maresso, Vanessa Sperandio

    Enterohemorrhagic E. coli (EHEC) is a natural human pathogen that poorly colonizes mice. Hence, the use of murine models to understand features of EHEC infection is a challenge.


  • Effect of substrate stiffness on human intestinal enteroids’ infectivity by enteroaggregative Escherichia coli

    by Ganesh Swaminathan, Nabiollah Kamyabi, Hannah E. Carter, Anubama Rajan, Umesh Karandikar, Zachary K. Criss, Noah F. Shroyer, Matthew J. Robertson, Cristian Coarfa, Chenlin Huang, et al.


  • Open Access

    Targeting of Mammalian Glycans Enhances Phage Predation in the Gastrointestinal Tract

    by Sabrina I. Green, Carmen Gu Liu, Xue Yu, Shelley Gibson, Wilhem Salmen, Anubama Rajan, Hannah E. Carter, Justin R. Clark, Xuezheng Song, Robert F. Ramig, et al.

    Invasive pathobionts or microbes capable of causing disease can reside deep within the mucosal epithelium of our gastrointestinal tract. Targeted effective antibacterial therapies are needed to combat these disease-causing organisms, many of which may be multidrug resistant.


  • Open Access

    Enteroaggregative E. coli Adherence to Human Heparan Sulfate Proteoglycans Drives Segment and Host Specific Responses to Infection

    by Anubama Rajan, Matthew J. Robertson, Hannah E. Carter, Nina M. Poole, Justin R. Clark, Sabrina I. Green, Zachary K. Criss, Boyang Zhao, Umesh Karandikar, Yikun Xing, et al.

    Enteroaggregative Escherichia coli (EAEC) is a significant cause of acute and chronic diarrhea, foodborne outbreaks, infections of the immunocompromised, and growth stunting in children in developing nations. There is no vaccine and resistance to antibiotics is rising. Unlike related E. coli pathotypes that are often associated with acute bouts of infection, EAEC is associated with persistent diarrhea and subclinical long-term colonization. Several secreted virulence factors have been associated with EAEC pathogenesis and linked to disease in humans, less certain are the molecular drivers of adherence to the intestinal mucosa. We previously established human intestinal enteroids (HIEs) as a model system to study host-EAEC interactions and aggregative adherence fimbriae A (AafA) as a major driver of EAEC adherence to HIEs. Here, we report a large-scale assessment of the host response to EAEC adherence from all four segments of the intestine across at least three donor lines for five E. coli pathotypes. The data demonstrate that the host response in the duodenum is driven largely by the infecting pathotype, whereas the response in the colon diverges in a patient-specific manner. Major pathways altered in gene expression in each of the four enteroid segments differed dramatically, with responses observed for inflammation, apoptosis and an overwhelming response to different mucin genes. In particular, EAEC both associated with large mucus droplets and specific mucins at the epithelial surface, binding that was ameliorated when mucins were removed, a process dependent on AafA. Pan-screening for glycans for binding to purified AafA identified the human ligand as heparan sulfate proteoglycans (HSPGs). Removal of HSPG abrogated EAEC association with HIEs. These results may mean that the human intestine responds remarkably different to distinct pathobionts that is dependent on the both the individual and intestinal segment in question, and uncover a major role for surface heparan sulfate proteoglycans as tropism-driving factor in adherence and/or colonization. E. coli is a significant cause of worldwide diarrhea and systemic infection. We previously established human intestinal enteroids as a model system to study E. coli-host interactions. We report the first large-scale assessment of the host response to infection from all four segments of the intestine across different donor lines for five different pathotypes. Whereas the host response in the duodenum is driven by the infecting pathotype, the response in the colon diverges by donor. We observed a major upregulation of host mucins, particularly for EAEC, which led to the identification of heparan sulfate proteoglycans (HSPGs) as the receptor on human colonoids. Our research highlights a new role for HSPGs for EAEC infection.


  • Open Access

    Enteropathogenic Escherichia coli Infection in Cancer and Immunosuppressed Patients

    by Adilene Olvera, Hannah Carter, Anubama Rajan, Lily G Carlin, Xiaomin Yu, Xi-Lei Zeng, Samuel Shelburne, Micah Bhatti, Sarah E Blutt, Noah F Shroyer, et al.

    The role of enteropathogenic Escherichia coli (EPEC) as a cause of diarrhea in cancer and immunocompromised patients is controversial. Quantitation of fecal bacterial loads has been proposed as a method to differentiate colonized from truly infected patients. We studied 77 adult cancer and immunosuppressed patients with diarrhea and EPEC identified in stools by FilmArray, 25 patients with pathogen-negative diarrhea, and 21 healthy adults without diarrhea. Stools were studied by quantitative polymerase chain reaction (qRT-PCR) for EPEC genes eaeA and lifA/efa-1 and strains characterized for virulence factors and adherence to human intestinal enteroids (HIEs). Patients with EPEC were more likely to have community-acquired diarrhea (odds ratio, 3.82 [95% confidence interval, 1.5–10.0]; P = .008) compared with pathogen-negative cases. Although EPEC was identified in 3 of 21 (14%) healthy subjects by qPCR, the bacterial burden was low compared to patients with diarrhea (≤55 vs median, 6 × 104 bacteria/mg stool; P < .001). Among EPEC patients, the bacterial burden was higher in those who were immunosuppressed (median, 6.7 × 103 vs 55 bacteria/mg; P < .001) and those with fecal lifA/ifa-1 (median, 5 × 104 vs 120 bacteria/mg; P = .015). Response to antimicrobial therapy was seen in 44 of 48 (92%) patients with EPEC as the sole pathogen. Antimicrobial resistance was common and strains exhibited distinct patterns of adherence with variable cytotoxicity when studied in HIEs. Cancer care was delayed in 13% of patients. Immunosuppressed cancer patients with EPEC-associated diarrhea carry high burden of EPEC with strains that are resistant to antibiotics, exhibit novel patterns of adherence when studied in HIEs, and interfere with cancer care.